An interview with a US-based key opinion leader (KOL) in which they provide insights into current prescribing habits as well as key marketed brands and their placement in the AML treatment algorithm. Key assets highlighted include Venclexta, Rydapt, Iomab-B, Onureg, quizartinib, gilteritinib, Rezlidhia, and entospletinib. 

This interview was conducted on 28 March 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.